Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Fred R. Hirsch, Keith M. Kerr, Paul A. Bunn, Edward S. Kim, Coleman Obasaju, Maurice Pérol, Philip Bonomi, Jeffrey D. Bradley, David Gandara, James R. Jett, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Suresh S. Ramalingam, Martin Reck, Craig H. Reynolds, Egbert F. Smit, Mark A. Socinski, David R. SpigelThomas E. Stinchcombe, Johan F. Vansteenkiste, Heather Wakelee, Nick Thatcher

Research output: Contribution to journalReview articleAcademicpeer-review


Patients with non–small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non–small-cell lung cancer, with a focus on SqCLC.
Original languageEnglish
Pages (from-to)331-339
Number of pages9
JournalClinical Lung Cancer
Issue number4
Publication statusPublished - 2018

Cite this